CDC1 prime and are licensed by CD4⁺ T cells to induce anti-tumour immunity.

ABSTRACT: Conventional type 1 dendritic cells (cDC1)¹ are thought to perform antigen cross-presentation, which is required to prime CD8⁺ T cells^2,3, whereas cDC2 are specialized for priming CD4⁺ T cells^4,5. CD4⁺ T cells are also considered to help CD8⁺ T cell responses through a variety of mechanisms^6-11, including a process whereby CD4⁺ T cells 'license' cDC1 for CD8⁺ T cell priming¹². However, this model has not been directly tested in vivo or in the setting of help-dependent tumour rejection. Here we generated an Xcr1^Cre mouse strain to evaluate the cellular interactions that mediate tumour rejection in a model requiring CD4⁺ and CD8⁺ T cells. A

SUBMITTER: Ferris ST 

PROVIDER: S-EPMC7469755 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature